Think of your gut lining as having a sugary coating that protects you. When this coating changes, it's like a tripwire that tells your immune system to attack, leading to diseases like Crohn's. This work identifies those specific sugar changes years before symptoms appear so doctors can stop the inflammation before it starts.
Crohn's disease is often diagnosed only after severe symptoms appear, missing the preclinical window where intervention is most effective. There is a lack of reliable biomarkers to identify at-risk individuals years before the onset of chronic inflammation.
The project is developing predictive tools for early detection of at-risk individuals and a new glyco-intervention strategy for disease prevention.
If you are a medical testing laboratory dealing with late-stage disease diagnosis — this project developed predictive tools that detect glycosylation changes in serum years before Crohn's disease diagnosis. This allows for early identification of at-risk individuals.
If you are a biotech drug developer dealing with the lack of preventative therapies for IBD — this project developed a glyco-intervention strategy to intercept the inflammation switch. This provides a new target for disease prevention drugs.
If you are a personalized nutrition company dealing with generic diet plans — this project developed insights into how diet and lifestyle maintain a healthy gut glycome. This enables the creation of targeted dietary interventions to prevent chronic inflammation.
Based on available project data, there is no specific pricing or cost information for the resulting tools, only the EU contribution of EUR 6,771,571 for research.
Based on available project data, the project is currently in the research and innovation phase; industrial scaling details are not yet specified.
Based on available project data, specific IP or licensing terms are not provided, though the project involves 4 industry partners who typically manage commercialization.
The project period runs from 2023-01-01 to 2028-12-31, suggesting that final results and tools will be available toward the end of 2028.
The project aims to create predictive tools for early detection and intervention strategies that can be used to manage health status and lifestyle before symptoms manifest.
The consortium is well-balanced for commercial translation, featuring a 40% industry ratio with 4 industrial partners and 2 SMEs. With 10 partners across 7 countries (including the US and UK), the project combines academic depth from 4 universities with industrial capacity, increasing the likelihood that the research will move toward a commercial product.
Contact I3S - Instituto de Investigacao e Inovacao em Saude da Universidade do Porto
Contact us to connect with the GlycanTrigger consortium for early licensing opportunities.
